Ambulatory Care Pharmacy Specialty Review Course, Workbook Chapters, and PRACTICE EXAM (No Recert Credit (Cert # L219101)

ACPE Numbers: Various – see listing below
Pre-Sale Date: N/A
Content Release Date: 06/16/2021
Expiration Date: 04/12/2022
Activity Type: Application-based
CE Credits: 25 hours (ACPE only)
Activity Fee: $475 (ASHP member); $675 (non-member)

Accreditation for Pharmacists

The American College of Clinical Pharmacy and American Society of Health-System Pharmacists are accredited by the Accreditation Council for Pharmacy Education as providers of continuing pharmacy education. 

Target Audience

These activities are intended for pharmacists who are seeking to update their knowledge and skills commensurate with a board certification examination in the areas listed below.

Activity Overview

Ambulatory Care Pharmacy Preparatory Review and Recertification Course is designed to help pharmacists who are preparing for the Board of Pharmacy Specialties certification examination in Ambulatory Care Pharmacy as well as those seeking a general review and refresher on disease states and therapeutics. The program goals are as follows:

  • To present a high-quality, up-to-date overview of disease states and therapeutics;
  • To provide a framework to help attendees prepare for the specialty certification examination in ambulatory care pharmacy; and
  • To offer participants an effective learning experience using a case-based approach with a strong focus on the thought processes needed to solve patient care problems in each therapeutic area. 

This course is NOT intended for those obtaining recertification credit. To earn recertification credit, please see courses here: 

These activities are part of the ACCP and ASHP professional development program.

Review Course

This course consists of 19 activities (see table below) and provides up to 24.5 hours of continuing pharmacy education credit. The Review Course includes case-based presentations for application to real-life scenarios, a practice exam along with correct answers, and links to the reference sources, and domains, tasks, and knowledge statements. To help you further prepare, this package includes a compilation of practice questions in the same format and rigor to help you prepare for the BPS Specialty Examination. 

For full program information, please visit:

Learning Activity

ACPE Number


Assessment Pass Point

Trial Design and Biostatistics



Endocrine Disorders



Genitourinary, Electrolytes, and Nutritional Deficiencies/Supplementation in Older Adults 



Group 1 Assessment 


Cardiology I




Cardiology II 



Bone/Joint and Rheumatology



Group 2 Assessment 


Diabetes Mellitus 







Pulmonary Disorders



Group 3 Assessment 


Practices and Processes of Care




Communication Strategies in Pharmacy



Developing and Managing a Clinical Practice



Group 4 Assessment 


Psychiatric Disorders







Gastrointestinal Disorders



Group 5 Assessment 


Infectious Diseases I 




Infectious Diseases II






Dermatologic and Eyes, Ears, Nose, and Throat, and Immunologic Disorders 



Group 6 Assessment 


Learning Objectives

At the end of the presentations, the pharmacist should be able to: 

Trial Design and Biostatistics
ACPE #: 0217-9999-21-050-H04-P

  • Describe hypothesistestingandstate themeaning ofand distinguishbetween p values andconfidenceintervals andmeasuresof centraltendency anddataspread.
  • Define,compare, and contrast theconceptsof internalandexternal validity,causation,association, bias, andconfounding in trial design. Selectstrategies to eliminateor control forbias and improve internaland externalvalidity.
  • Compare andcontrast theadvantagesand disadvantages ofvarious study designs (e.g.,prospective,retrospective,case-control, cohort, cross-sectional, randomizedcontrolled clinicaltrials, systematic review,meta-analysis).
  • Determine why astatisticaltestis appropriateor notappropriate, giventhe sample distribution,data type, and study design. Interpret statistical and clinical significancefor resultsfromcommonlyused statistical tests.
  • Defineand evaluate odds ratio, risk/incidence rate,relativerisk, number neededtotreat,number needed toharm, and other riskestimates. 

Endocrine Disorders
ACPE #: 0217-9999-21-051-H01-P

  • Identify appropriate thyroid hormone replacement therapy dosing strategies for patients with hypothyroidism and hyperthyroidism.
  • Recommend appropriate patient-specific pharmacotherapy for the treatment of polycystic ovary syndrome.
  • Medically manage a patient with hyperprolactinemia, acromegaly, and growth hormone deficiency.
  • Differentiate between the available weight-loss medications with respect to mechanism of action, efficacy, and adverse effects, and design a patient-specific treatment plan.
  • Recognize the clinical presentation of a patient with adrenal gland disorders and Cushing disease and design a treatment plan.
  • Compare the safety, efficacy, and routes of administration of available testosterone (T) replacement products and list appropriate monitoring guidelines for hypogonadism. 

Genitourinary, Electrolytes, and Nutritional Deficiencies/Supplementation in Older Adults
ACPE #: 0217-9999-21-049-H01-P

  • Identify and assess common genitourinary diseases, electrolyte abnormalities, and nutritional deficiencies that occur in ambulatory older adults.
  • Evaluate and manage drug-induced causes of benign prostatic hyperplasia (BPH), urinary incontinence, erectile dysfunction (ED), and electrolyte  and vitamin abnormalities in ambulatory older adults.
  • Compare and contrast pharmacologic interventions for BPH, urinary incontinence, ED, electrolyte abnormalities, and nutritional deficiencies.
  • Formulate treatment strategies for BPH, urinary incontinence, ED, electrolyte abnormalities, and nutritional deficiencies using patient-specific information. 

Cardiology I
ACPE #: 0217-9999-21-052-H01-P

  • Evaluate the appropriate use of aspirin for primary prevention of cardiovascular (CV) events according to practice guidelines and clinical trial evidence.
  • Design an evidence-based treatment and monitoring strategy for patients with hypertension (HTN) that considers goals of therapy, comorbid conditions, and compelling indications.
  • Formulate a treatment plan for resistant HTN.
  • Create an evidence-based treatment and monitoring plan for patients receiving lipid-lowering therapies for primary and secondary prevention of atherosclerotic cardiovascular disease (ASCVD) and hypertriglyceridemia.
  • Develop an optimal treatment strategy for patients who experience statin-associated muscle symptoms or are statin intolerant.
  • Devise an evidence-based treatment plan for secondary prevention of acute coronary syndrome (ACS), stroke and transient ischemic attack (TIA), and peripheral arterial disease (PAD).
  • Recommend an appropriate time interval for discontinuing antiplatelet medications for surgical procedures. 

Cardiology II
ACPE #: 0217-9999-21-053-H01-P

  • Formulate appropriate oral anticoagulant treatment strategies for patients who develop venous thromboembolism (deep venous thrombosis or pulmonary embolism), nonvalvular atrial fibrillation (NVAF), or who have mechanical heart valves consistent with available consensus panel guidelines, recent U.S. Food and Drug Administration approvals, and randomized clinical trials.
  • Describe key differences in onset of action, dosing, administration, absorption, effects on common coagulation tests, and drug interactions between dabigatran, rivaroxaban, apixaban, edoxaban, and warfarin.
  • Develop patient-specific, guideline-driven treatment, monitoring, and follow-up plans for patients with heart failure (HF), atrial fibrillation (AF), or ventricular tachycardia..
  • Identify treatment goals, common adverse effects, clinically important drug interactions, monitoring, and risk evaluation and mitigation strategies requirements for oral pharmacotherapy of pulmonary arterial hypertension. 

Bone/Joint and Rheumatology
ACPE #: 0217-9999-21-054-H01-P

  • Systematically identify patients to screen for osteoporosis, and use the screening results to guide the decision on how to treat the patient.
  • Use a STEPS-wise approach (safety, tolerability, efficacy, preference [pearls], simplicity) for comparing, recommending, and justifying a drug therapy regimen for osteoporosis, rheumatoid arthritis (RA), psoriatic arthritis (PsA), osteoarthritis (OA), fibromyalgia, gout, and systemic lupus erythematosus (SLE).
  • Choose a drug therapy for osteoarthritis or fibromyalgia syndrome on the basis of drug efficacy and a patient’s comorbid conditions.
  • Select screenings or laboratory tests at correct intervals for patients with rheumatoid arthritis, psoriatic arthritis, or systemic lupus erythematous treated with disease-modifying antirheumatic drug (DMARD) or biologic therapies.
  • Formulate a care plan to help patients decrease their uric acid concentrations, gout symptoms, and gouty attacks using nonpharmacologic and pharmacologic interventions. 

Diabetes Mellitus
ACPE #: 0217-9999-21-055-H01-P

  • Identify differences between prediabetes, type 1 diabetes mellitus (T1DM), type 2 diabetes mellitus (T2DM), and gestational diabetes mellitus (GDM), including differences in diagnostic criteria and clinical presentation.
  • Describe the pathophysiology of T1DM and T2DM.
  • Compare agents used in the treatment of diabetes mellitus (DM), including their mechanisms of action, adverse effects, contraindications, advantages, and disadvantages for each agent discussed.
  • Select appropriate insulin regimens for patients on the basis of desired onset, peak, and duration of insulin effects.
  • Individualize a comprehensive glycemic treatment and monitoring plan for a patient with prediabetes, DM, and GDM.
  • Discuss appropriate blood pressure and lipid management for patients with DM.
  • Discuss the acute and chronic complications associated with DM and strategies to prevent or slow their progression. 

Obstetrics and Gynecology
ACPE #: 0217-9999-21-056-H01-P

  • Recommend therapy for contraception, infertility, menstrual disorders, and endometriosis on the basis of patient-specific information.
  • Recommend appropriate treatment for common acute and chronic conditions in pregnancy and lactation.
  • Recommend therapy for menopause on the basis of patient-specific information.
  • Develop provider and patient education regarding medication use during pregnancy and lactation, contraception, infertility, menstrual disorders, endometriosis, and postmenopausal therapy. 

Pulmonary Disorders
ACPE #: 0217-9999-21-057-H01-P

  • Compare and contrast between common features of patients with asthma, chronic obstructive pulmonary disease (COPD), or both.
  • Select appropriate evidence-based treatment for patients with asthma, COPD, and/or nicotine dependence based on specific patient factors and comorbidities.
  • Develop a comprehensive education plan with monitoring parameters for patients on therapy for asthma, COPD, and/or smoking cessation.
  • Compare and contrast the different respiratory inhaler devices and holding chambers.
  • Integrate brief behavioral counseling and smoking cessation best practices when assisting a patient with quitting smoking.
  • Explain the public health, practice management, and patient advocacy issues as they pertain to asthma, COPD, and/or smoking cessation. 

Practices and Processes of Care
ACPE #: 0217-9999-21-058-H04-P

  • Discuss issues with transitions of care and a pharmacist’s role in achieving quality measures and improving the process.
  • Describe different types of patient care services or practice models provided by a pharmacist within an ambulatory practice, together with any applicable regulatory requirements.
  • Apply tools and resources to detect, classify, report, analyze, and reduce preventable and non- preventable adverse drug events.
  • Use formulary management activities and other resources to improve the prescribing of and access to safe, effective, and affordable treatments in an organization. 

Communication Strategies in Pharmacy
ACPE #: 0217-9999-21-059-H04-P

  • Use strategies that develop patient rapport, foster trust, and effectively and efficiently obtain accurate, comprehensive histories, despite potential barriers in communication.
  • Use assessments of patients’ knowledge, health literacy, self-management skills, health beliefs, and attitudes toward medications to tailor educational interventions that will improve adherence and self- efficacy.
  • Communicate patient care activities and medication-related information effectively to other health care professionals verbally and in writing through the medical record.
  • Discuss factors and methods used to assess and select appropriate written educational materials intended for the general public. 

Developing and Managing a Clinical Practice
ACPE #: 0217-9999-21-060-H04-P

  • Perform an internal and external environmental scan and needs assessment to determine the need for and organizational value of an ambulatory pharmacist–provided patient care service.
  • Discuss steps to implement an ambulatory service, including identifying key stakeholders and developing essential clinic operational activities.
  • Develop a robust and sustainable quality assessment program using the balanced scorecard concept for your clinical service and identifying quality measures important to your organization and patient population.
  • Develop a credentialing and privileging process to ensure the competency of pharmacists providing direct patient care in your ambulatory service.
  • Identify and implement revenue-generating opportunities for pharmacist-provided patient care services in different ambulatory care settings. 

Psychiatric Disorders
ACPE #: 0217-9999-21-061-H01-P

  • Analyze the Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5) criteria and disease course for anxiety disorders, sleep disorders, major depression, bipolar disorder, attention-deficit/hyperactivity disorder, schizophrenia, and substance use disorders.
  • Apply a working knowledge of common drug and nondrug therapies for psychiatric disorders, including drug, dose, frequency, adverse effects, drug interactions, and monitoring values.
  • Recommend appropriate treatments, including both lifestyle modification and specific drug therapy (medication dose, schedule, and delivery system), on the basis of relevant patient factors (pharmacodynamic, physiologic, pharmacokinetic, and socioeconomic parameters).
  • Monitor for adverse drug effects, drug-drug and drug-disease interactions, and appropriateness of therapy, including polytherapy. 

ACPE #: 0217-9999-21-062-H01-P

  • Given a patient case, select an appropriate antiepileptic drug (AED) regimen for a patient with epilepsy on the basis of seizure type and AED mechanism of action, common adverse effects, and drug interactions.
  • Recommend an appropriate pharmacologic therapy for a patient with episodic or chronic migraine headache.
  • Recommend and manage appropriate disease-modifying therapy for a patient with multiple sclerosis (MS) on the basis of MS subtype and other patient-specific factors.
  • Formulate a treatment plan for a patient with Parkinson disease.
  • Recommend an appropriate pharmacologic therapy for a patient with neuropathic pain. 

Gastrointestinal Disorders
ACPE #: 0217-9999-21-063-H01-P

Gastrointestinal (GI) disorders within the objectives refer to the disorders covered in this chapter and include the following: gastroesophageal reflux disease, peptic ulcer disease, chronic liver disease manifestations, viral hepatitis, malabsorption syndrome, diarrhea, constipation, nausea and vomiting, irritable bowel syndrome, and inflammatory bowel disease.

  • Evaluate and apply national guideline–based treatment strategies for gastrointestinal (GI) disorders.
  • Assess the benefits and risks of drug therapy for patients with GI disorders.
  • Recommend appropriate nonpharmacologic and pharmacologic interventions for managing GI disorders.
  • Develop and implement a patient-specific comprehensive therapeutic plan for managing GI disorders.
  • Provide drug-related patient education and counseling for pharmacologic therapies used in managing GI disorders. 

Infectious Diseases I
ACPE #: 0217-9999-21-064-H02-P

  • Identify the clinical presentations of sexually transmitted infections, and design appropriate treatment regimens.
  • Describe the mechanisms of action and adverse effects associated with antiretroviral agents, and identify major drug interactions associated with them.
  • Formulate treatment strategies for the management of HIV and commonly encountered opportunistic infections.
  • Design appropriate strategies for treatment and prevention of influenza and other viral infections.
  • Explain the risk factors for superficial and endemic fungal infections, and design corresponding treatment regimens. 

Infectious Diseases II
ACPE #: 0217-9999-21-065-H01-P

  • Design appropriate pharmacologic and nonpharmacologic treatment regimens for patients with urinary tract infections, prostatitis, community-acquired pneumonia, sinusitis, pharyngitis, acute otitis media, skin and soft tissue infections, latent tuberculosis infection, conjunctivitis, Lyme disease, antibiotic prophylaxis, infectious diarrhea, and Clostridioides difficile infections.
  • Identify risk factors and clinical circumstances for antimicrobial resistance.
  • Design an antimicrobial therapeutic regimen to treat resistant infections and prevent their future development.
  • Apply evidence-based medicine and patient-specific factors to design antimicrobial regimens that are appropriate and cost-effective for the patient. 

ACPE #: 0217-9999-21-066-H01-P

  • Identify a patient at risk of developing, or presenting with, acute kidney injury, drug-induced kidney disease, or chronic kidney disease (CKD), and formulate an appropriate care plan to mitigate risk and slow progression.
  • Using appropriate data, assess kidney function, dialysis regimen information, and pharmacokinetic/pharmacodynamic drug properties in a patient to inform clinical decision- making.
  • Formulate an evidence-based treatment plan for managing the most common medical problems in patients with CKD, including anemia, CKD-related mineral and bone disorder, and hyperkalemia.
  • Describe Medicare Part B and D policies related to end-stage renal disease (ESRD) and dialysis care (i.e., ESRD Prospective Payment System, Quality Incentive Program, Conditions for Coverage, Centers for Medicare & Medicaid Services Comprehensive ESRD Care Model) and their respective effects on medication use. 

Dermatologic and Eyes, Ears, Nose, and Throat, and Immunologic Disorders
ACPE #: 0217-9999-21-067-H01-P

  • Formulate an ophthalmologic drug therapy regimen for a patient presenting with macular degeneration, dry eye syndrome, or glaucoma.
  • Construct an individualized pharmacy care plan for a patient with allergic rhinitis.
  • Using a treatment algorithm, initiate, change, and modify topical and oral therapeutic regimens for acne.
  • Recommend single or multiple topical and systemic agents for treating plaque psoriasis given a patient’s disease presentation, severity, and prior therapies.
  • Effectively educate a patient presenting with a skin infestation or minor burn on the purpose, proper use, and potential adverse reactions of the first-line treatment options. 


Full Faculty Information

Katie E. Cardone, Pharm.D., BCACP FNKF, FASN, FCCP
Associate Professor
Albany College of Pharmacy and Health Sciences
Albany, New York

Erica Crannage, Pharm.D., BCPS, BCACP, FCCP
Associate Professor
St. Louis College of Pharmacy;
Clinical Pharmacist
St. Louis University Family and Community Medicine
Saint Louis, Missouri

Spencer H. Durham, Pharm.D., BCPS, BCIDP
Assistant Clinical Professor
Department of Pharmacy Practice
Auburn University Harrison School of Pharmacy
Auburn, Alabama

Jessica Farrell, Pharm.D.
Clinical Pharmacist/Associate Professor
Albany College of Pharmacy and Health Sciences
The Center for Rheumatology
Albany, New York

Alicia B. Forinash, Pharm.D., FCCP, BCPS, BCACP
Professor of Pharmacy Practice
St. Louis College of Pharmacy
St. Louis, Missouri

Nicole M. Hahn, Pharm.D., BCACP*
Clinical Pharmacy Specialist – Neurology
Kaiser Permanente
Denver, Colorado

Adam B. Jackson, Pharm.D., BCACP*
Clinical Pharmacy Specialist 
Pharmacy Department
Kaiser Permanente Colorado
Denver, Colorado

Associate Professor
Department of Clinical Pharmacy University of Colorado
Skaggs School of Pharmacy and Pharmaceutical Sciences
Aurora, Colorado

Michelle T. Martin, Pharm.D., BCPS, BCACP, FCCP
Clinical Pharmacist and Clinical Associate Professor
University of Illinois Hospital and Health Sciences System
University of Illinois at Chicago College of Pharmacy
Chicago, Illinois

Jamie L. McConaha, Pharm.D., BCACP*, CDE
Associate Professor of Pharmacy Practice
Duquesne University School of Pharmacy
Pittsburgh, Pennsylvania

Emily McCoy, Pharm.D., BCACP
Associate Clinical Professor
Auburn University Harrison School of Pharmacy
Mobile, Alabama

Molly G. Minze, Pharm.D., BCACP, FCCP
Associate Professor, Department of Pharmacy Practice
Texas Tech University Health Sciences Center Jerry H. Hodge School of Pharmacy
Abilene, Texas

Jean Y. Moon, Pharm.D., BCACP, FCCP
Associate Professor
University of Minnesota College of Pharmacy
Minneapolis, Minnesota

Melissa C. Palmer, Pharm.D., BCPS, BCPP
Clinical Pharmacy Specialist – Mental Health
Alaska VA Healthcare System
Anchorage, Alaska

Katie Suda, Pharm.D., M.S.
Research Health Scientist and Associate Director of Clinical Therapeutics
VA Center for Health Equity Research and Promotion
Professor of Medicine
University of Pittsburgh School of Medicine
Pittsburgh, Pennsylvania

Jessica Tilton, Pharm.D., BCACP
Clinical Assistant Professor
Clinical Coordinator
Medication Therapy Management Clinic
University of Illinois at Chicago College of Pharmacy
Chicago, Illinois

Liz Van Dril, Pharm.D., BCPS, BCACP
Clinical Assistant Professor/Clinical Pharmacist
University of Illinois at Chicago College of Pharmacy/UI Health
Chicago, Illinois 

Valerie A. Vuylsteke, Pharm.D., BCACP
Pharmacy Clinical Specialist- Ambulatory Care, PGY2 Transitions of Care Pharmacy Residency Program Director
Methodist Dallas Medical Center- Golden Cross Academic Clinic
Dallas, Texas

*Content Matter Experts 


Jennifer Bean, Pharm.D., BCPS, BCPP
Craig J. Beavers, Pharm.D., FCCP, FACC, FAHA, BCCP, BCPS-AQ Cardiology, CACP
Brittany D. Bissell, Pharm.D., Ph.D., BCCCP
Wiyanna K. Bruck, Pharm.D., BCIDP
Megan Fleischman, Pharm.D., BCACP
Rim M. Hadgu, Pharm.D.
Rick Hess, Pharm.D., BCACP, CDE
Diana Isaacs, Pharm.D., FADCES, BCPS, BCACP, BC-ADM, CDCES
Sum Lam, Pharm.D., BCGP, BCPS
Rachel MacLeod (Garrity), Pharm.D., BCIDP, AAHIVP
Christina M. Madison, Pharm.D., FCCP, AAHIVP
Sallie D. Mayer, Pharm.D., MBA, BCPS, CDCES
Scott Pearson, Pharm.D., BCACP
Ann M. Philbrick, Pharm.D., FCCP, BCPS, BCACP
Lindsay M. Saum, Pharm.D., BCPS, BCGP
Sneha Baxi Srivastava, Pharm.D., BCACP, CDCES, DipACLM
Lori Wilken, Pharm.D., BCACP, NCTTP, AE-C
Susan R. Winkler, Pharm.D., FCCP, BCPS

Field Testers

Jennifer Banks, Pharm.D, BCPS, BCACP, BCGP, CDCES, BA-ADM, AE-C
Kaci Boehmer, Pharm.D., BCACP
Megan Chynoweth, Pharm.D., CDE, BCACP
Frank Fanizza, Pharm.D., BCACP, AAHIVP
Jeffrey Freund, Pharm.D., BCACP
Irene Hanna, Pharm.D, BCACP, CDCES
Patrick Hryshko, Pharm.D., BCACP
Amy Ibrahim, Pharm.D., BCACP, CTTS
Carey Jones, BCACP, BCPS
Aleia Judd, Pharm.D., BCACP
Gayle Kamm, Pharm.D.
Rebecca Khaimova, Pharm.D., BCACP
Yaeji Kim, Pharm.D., BCACP
Saskia Leather, Pharm.D., BCACP
Maureen Lloy, Pharm.D., BCACP
Matthew Maddox, Pharm.D., BCACP, BCGP, CPH
Mardoqueo Martinez, Pharm.D., BCACP
Ellina Max, Pharm.D., BCACP
Sarah McGill, Pharm.D., BCACP
Emma Merrells, R.Ph., BCACP, BCGP
Kristen Miezianko, Pharm.D., BCPS
Katherine Montag Schafer, Pharm.D., BCACP, CDCES
Amit Patel, Pharm.D., BCACP
Lauren Peyton, Pharm.D., BCACP, CDCES
Melanie Proffitt, Pharm.D., BCACP, MHA
Krystal Riccio, Pharm.D., BCACP, CDCES
Shelly Rutledge, Pharm.D., BCACP
Roberta Sposato, R.Ph., BCACP, MBA
Kenyu Tan, Pharm.D., BCACP, BCPS, BCGP
Chris Terpening, Ph.D., Pharm.D., BCACP
Emily Walsh, Pharm.D., BCACP
Hilary Weismantel, Pharm.D., BCACP


In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support and the Accreditation Council for Pharmacy Education’s Standards for Commercial Support, ACCP and ASHP requires that all individuals involved in the development of activity content disclose their relevant financial relationships. A person has a relevant financial relationship if the individual of his or her spouse/partner has a financial relationship (e.g. employee, consultant, research grant recipient, speakers bureau, or stockholder) in any amount occurring the in the last 12 months with a commercial interest whose products or series may be discussed in the educational activity content over which the individual has control. The existence of these relationships is provided for the information of participants and should not be assumed to have an adverse impact on the content.

All faculty and planners for ACCP and ASHP education activities are qualified and selected by ACCP and ASHP required to disclose any relevant financial relationships with commercial interests. ACCP and ASHP identifies and resolves conflicts of interest prior to an individual’s participation in development of content for an educational activity. Anyone who refuses to disclose relevant financial relationships must be disqualified from any involvement with a continuing pharmacy education activity.

Faculty Disclosures:

  • Consultant/Member of Advisory Board: Katie E. Cardone (Wolters Kluwer, AstraZeneca), Jessica Farrell (Cumberland Pharmaceuticals, Gilead, Boehringer Ingelheim), Michelle T. Martin (AbbVie), Molly G. Minze (Wolters Kluwer)
  • Grant Funding/Research Support: Jessica Farrell (Janssen Pharmaceuticals), Michelle T. Martin (Merck), Melissa C. Palmer (Telehealth ECHO)
  • Speaker’s Bureau: Jessica Farrell (Pfizer, AbbVie)
  • Minor Shareholder: Michelle T. Martin (AbbVie, Gilead, and Merck)
  • Employer: Katie E. Cardone (Spouse employed by Fresenius Medical Care), Alicia B. Forinash (Spouse employed by Bayer)
  • Other: Alicia B. Forinash (royalties from Wolters Kluwer) 

Reviewer Disclosures:

  • Consultant/Member of Advisory Board: Christina Madison (GoodRx, Pills2Me, Boomer Naturals Holdings), Diana Issacs (Lifespan, Lilly).
  • Speaker’s Bureau: Christina Madison (Janssen Therapeutics, Gilead Sciences), Diana Isaacs (Xeris, Novo Nordisk, Medtronic, Dexcom, Abbott)

Field Tester Disclosures:

  • Employee:  Shelly Rutledge (Providence Health Plan)
  • Stockholder: Megan Chynoweth (JNJ), Kenyu Tan (CVS Pharmacy)

Methods and CE Requirements

Activities can be completed in any order. Each activity consists of audio, video, and/or PDFs and evaluations. Learners must review all content and complete the evaluations to receive continuing pharmacy education credit for each activity.

Follow the prompts to claim, view, or print the statement of credit within 60 days after completing the activity.

System Technical Requirements

Courses and learning activities are delivered via your Web browser and Acrobat PDF. For all activities, you should have a basic comfort level using a computer and navigating web sites.

View the minimum technical and system requirements for learning activities.


These activities were developed by ACCP and ASHP.

To maintain its strict, independent standards for certification, BPS does NOT endorse or provide review information, preparatory courses, or study guides for Board Certification Examinations.